Disease Areas
News and analysis on disease research and diagnostics.
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
Vir Biotechnology Completes Licensing Deal With Sanofi for Three T-Cell Engager Programs
Vir gained exclusive worldwide rights to HER2-targeted, PSMA-targeted, and EGFR-targeted T-cell engager assets.
In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.
Cancer Diagnostics Firm Syantra Raises $3.6M in Series A-1 Round
The University of Calgary spinout aims to commercialize a liquid biopsy test that measures mRNA biomarkers for the early detection of breast cancer.